Key result
Slow-release isradipine significantly reduced urinary albumin excretion (P<0.05) and achieved blood pressure normalization in 100% of low-renin versus 57% of high/medium-renin patients.
Why the study?
Does slow-release isradipine reduce blood pressure and improve renal parameters in patients with mild to moderate essential hypertension, and does efficacy vary by baseline plasma renin activity?
Population
26 patients with mild to moderate essential hypertension, stratified by plasma renin activity into…
Comparison
Slow-release isradipine 2.5-5 mg for 12 weeks vs Placebo
Design
RCT, Randomly assigned
Follow-up
12 weeks
Authors
Loading...
Supports renin-stratified isradipine use in hypertension; extends RCT evidence on differential BP responses by baseline renin activity.
RCT (n=26)
Randomly assigned
Does slow-release isradipine reduce blood pressure and improve renal parameters in patients with mild to moderate essential hypertension, and does efficacy vary by baseline plasma renin activity?
p-value: p=<0.05
Isradipine effectively reduces blood pressure and urinary albumin excretion in essential hypertension, with a more pronounced antihypertensive effect in patients with low baseline plasma renin activity.
Allikmets et al. (1997) conducted an RCT in Mild to moderate essential hypertension (n=26). Slow-release isradipine vs. Placebo was evaluated on Blood pressure (BP) decrease and normalization (p=<0.05). Slow-release isradipine significantly reduced urinary albumin excretion (P<0.05) and achieved blood pressure normalization in 100% of low-renin versus 57% of high/medium-renin patients.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: